Literature DB >> 29600406

[Selective mutism].

J Rogoll1, M Petzold2, A Ströhle3.   

Abstract

Selective mutism was first described in the medical literature 140 years ago. The diagnosis came into the focus of adult psychiatry with the appearance of DSM-5. Henceforth, selective mutism during infancy, adolescence and also adulthood is specified as an independent anxiety disorder. It often begins in early childhood with a kind of speechlessness in certain situations. A diagnostic clarification often only takes place after school enrolment. Very often comorbid anxiety disorders, especially social phobia and depression also occur. The course is very variable and with some affected persons regression of the pathology occurs suddenly and completely and with others there is a slow regression of the symptoms. Equally the disorder can persist until adulthood. Whilst formerly a traumatic genesis was assumed, a multifactorial etiology with genetic, psychological and language-associated effects is nowadays presumed. The therapy is supported through psychotherapy, speech therapy and psychopharmacology.

Entities:  

Keywords:  Comorbidities; Etiology; Pharmacotherapy; Psychotherapy; Social phobia

Mesh:

Year:  2018        PMID: 29600406     DOI: 10.1007/s00115-018-0504-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  26 in total

Review 1.  The use of medication in selective mutism: a systematic review.

Authors:  Katharina Manassis; Beate Oerbeck; Kristin Romvig Overgaard
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-11-09       Impact factor: 4.785

2.  Group therapy for selective mutism - a parents' and children's treatment group.

Authors:  Louise Sharkey; Fiona Mc Nicholas; Edwina Barry; Maire Begley; Sinead Ahern
Journal:  J Behav Ther Exp Psychiatry       Date:  2008-01-25

3.  Behavioral intervention to treat selective mutism across multiple social situations and community settings.

Authors:  Russell Lang; April Regester; Austin Mulloy; Mandy Rispoli; Amanda Botout
Journal:  J Appl Behav Anal       Date:  2011

4.  A common genetic variant in the neurexin superfamily member CNTNAP2 is associated with increased risk for selective mutism and social anxiety-related traits.

Authors:  Murray B Stein; Bao-Zhu Yang; Denise A Chavira; Carla A Hitchcock; Sharon C Sung; Elisa Shipon-Blum; Joel Gelernter
Journal:  Biol Psychiatry       Date:  2010-12-30       Impact factor: 13.382

5.  Selective mutism and comorbidity with developmental disorder/delay, anxiety disorder, and elimination disorder.

Authors:  H Kristensen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-02       Impact factor: 8.829

6.  Selective mutism: more than social anxiety?

Authors:  Robin Yeganeh; Deborah C Beidel; Samuel M Turner
Journal:  Depress Anxiety       Date:  2006       Impact factor: 6.505

7.  Selective mutism and temperament: the silence and behavioral inhibition to the unfamiliar.

Authors:  Angelika Gensthaler; Sally Khalaf; Marc Ligges; Michael Kaess; Christine M Freitag; Christina Schwenck
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-03-12       Impact factor: 4.785

8.  Treating youths with selective mutism with an alternating design of exposure-based practice and contingency management.

Authors:  Jennifer Vecchio; Christopher A Kearney
Journal:  Behav Ther       Date:  2008-11-03

9.  Comparing interventions for selective mutism: a pilot study.

Authors:  Katharina Manassis; Rosemary Tannock
Journal:  Can J Psychiatry       Date:  2008-10       Impact factor: 4.356

Review 10.  [Anxiety disorders in DSM-5: an overview on changes in structure and content].

Authors:  H-U Wittchen; I Heinig; K Beesdo-Baum
Journal:  Nervenarzt       Date:  2014-05       Impact factor: 1.214

View more
  2 in total

1.  The Diagnosis and Treatment of Anxiety Disorders.

Authors:  Andreas Ströhle; Jochen Gensichen; Katharina Domschke
Journal:  Dtsch Arztebl Int       Date:  2018-09-14       Impact factor: 5.594

2.  [Update on anxiety disorders-current state and new developments].

Authors:  K Domschke
Journal:  Nervenarzt       Date:  2021-04-30       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.